blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2747781

EP2747781 - BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.09.2018
Database last updated on 11.05.2024
FormerThe patent has been granted
Status updated on  13.10.2017
FormerGrant of patent is intended
Status updated on  08.06.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Roche Glycart AG
Wagistrasse 18
8952 Schlieren / CH
[2014/27]
Inventor(s)01 / BRUENKER, Peter
Burgwiesenstrasse 3c
CH-8335 Hittnau / CH
02 / FAUTI, Tanja
Ruetihoferstrasse 46
CH-8049 Zuerich / CH
03 / JAEGER, Christiane
Guggenbuehlstrasse 12
CH-Wallisellen 8304 / CH
04 / KLEIN, Christian
Chruezacherweg 41
CH-8906 Bonstetten / CH
05 / UMANA, Pablo
Felsenrainstrasse 28
CH-8832 Wollerau / CH
 [2014/27]
Representative(s)Townsend, Carolin, et al
F. Hoffmann-La Roche AG
Patent Department
Grenzacherstrasse 124
4070 Basel / CH
[2014/27]
Application number, filing date12748490.521.08.2012
[2017/46]
WO2012EP66226
Priority number, dateEP2011017841023.08.2011         Original published format: EP 11178410
[2014/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013026839
Date:28.02.2013
Language:EN
[2013/09]
Type: A1 Application with search report 
No.:EP2747781
Date:02.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 28.02.2013 takes the place of the publication of the European patent application.
[2014/27]
Type: B1 Patent specification 
No.:EP2747781
Date:15.11.2017
Language:EN
[2017/46]
Search report(s)International search report - published on:EP28.02.2013
ClassificationIPC:A61K39/395, A61P35/00, C07K16/30
[2014/27]
CPC:
C07K16/468 (EP,US); C07K16/46 (KR); A61K39/395 (KR);
A61P35/00 (EP); C07K16/30 (EP,KR,US); C07K16/3053 (US);
C07K16/2809 (EP,US); C07K2317/31 (EP,US); C07K2317/52 (US);
C07K2317/55 (EP,US); C07K2317/66 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/27]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BISPEZIFISCHE ANTIKÖRPER SPEZIFISCH FÜR T-ZELL-AKTIVIERENDE ANTIGENE UND EIN TUMORANTIGEN SOWIE VERWENDUNGSVERFAHREN[2017/27]
English:BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE[2014/27]
French:ANTICORPS BISPÉCIFIQUES SPÉCIFIQUES POUR LES ANTIGÈNES D'ACTIVATION DES LYMPHOCYTES T ET UN ANTIGÈNE TUMORAL ET PROCÉDÉS D'UTILIATION CORRESPONDANTS[2014/27]
Former [2014/27]BISPEZIFISCHE ANTIKÖRPER SPEZIFISCH FÜR T-ZELL-AKTIVIERENDEN ANTIGENE UND EIN TUMORANTIGEN SOWIE VERWENDUNGSVERFAHREN
Entry into regional phase24.03.2014National basic fee paid 
24.03.2014Designation fee(s) paid 
24.03.2014Examination fee paid 
Examination procedure24.03.2014Examination requested  [2014/27]
18.09.2014Amendment by applicant (claims and/or description)
20.01.2016Despatch of a communication from the examining division (Time limit: M04)
24.06.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
12.08.2016Reply to a communication from the examining division
09.06.2017Communication of intention to grant the patent
05.10.2017Fee for grant paid
05.10.2017Fee for publishing/printing paid
05.10.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.01.2016
Opposition(s)17.08.2018No opposition filed within time limit [2018/43]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
12.08.2016Request for further processing filed
12.08.2016Full payment received (date of receipt of payment)
Request granted
29.08.2016Decision despatched
Fees paidRenewal fee
07.08.2014Renewal fee patent year 03
07.08.2015Renewal fee patent year 04
05.08.2016Renewal fee patent year 05
10.08.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.08.2012
AL15.11.2017
AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
MC15.11.2017
MK15.11.2017
NL15.11.2017
PL15.11.2017
PT15.11.2017
RO15.11.2017
RS15.11.2017
SE15.11.2017
SI15.11.2017
SK15.11.2017
SM15.11.2017
TR15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
IS15.03.2018
[2020/33]
Former [2020/31]HU21.08.2012
AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
MC15.11.2017
MK15.11.2017
NL15.11.2017
PL15.11.2017
PT15.11.2017
RO15.11.2017
RS15.11.2017
SE15.11.2017
SI15.11.2017
SK15.11.2017
SM15.11.2017
TR15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2020/28]HU21.08.2012
AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
MC15.11.2017
NL15.11.2017
PL15.11.2017
PT15.11.2017
RO15.11.2017
RS15.11.2017
SE15.11.2017
SI15.11.2017
SK15.11.2017
SM15.11.2017
TR15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2020/16]AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
MC15.11.2017
NL15.11.2017
PL15.11.2017
RO15.11.2017
RS15.11.2017
SE15.11.2017
SI15.11.2017
SK15.11.2017
SM15.11.2017
TR15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2019/15]AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
MC15.11.2017
NL15.11.2017
PL15.11.2017
RO15.11.2017
RS15.11.2017
SE15.11.2017
SI15.11.2017
SK15.11.2017
SM15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2018/52]AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
NL15.11.2017
PL15.11.2017
RO15.11.2017
RS15.11.2017
SE15.11.2017
SI15.11.2017
SK15.11.2017
SM15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2018/40]AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
NL15.11.2017
PL15.11.2017
RO15.11.2017
RS15.11.2017
SE15.11.2017
SK15.11.2017
SM15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2018/39]AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
IT15.11.2017
LT15.11.2017
LV15.11.2017
NL15.11.2017
PL15.11.2017
RS15.11.2017
SE15.11.2017
SK15.11.2017
SM15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2018/37]AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
LT15.11.2017
LV15.11.2017
NL15.11.2017
PL15.11.2017
RS15.11.2017
SE15.11.2017
SK15.11.2017
SM15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2018/35]AT15.11.2017
CY15.11.2017
CZ15.11.2017
DK15.11.2017
EE15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
LT15.11.2017
LV15.11.2017
NL15.11.2017
RS15.11.2017
SE15.11.2017
SK15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2018/24]AT15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
LT15.11.2017
LV15.11.2017
NL15.11.2017
RS15.11.2017
SE15.11.2017
BG15.02.2018
NO15.02.2018
GR16.02.2018
Former [2018/23]AT15.11.2017
ES15.11.2017
FI15.11.2017
HR15.11.2017
LT15.11.2017
NL15.11.2017
RS15.11.2017
SE15.11.2017
NO15.02.2018
GR16.02.2018
Former [2018/22]ES15.11.2017
FI15.11.2017
LT15.11.2017
NL15.11.2017
NO15.02.2018
Cited inInternational search[Y]WO2009080254  (HOFFMANN LA ROCHE [CH], et al) [Y] 1-22 * figure 3 *;
 [Y]  - OSHIMI ET AL, "Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.", BLOOD, (19910301), vol. 77, no. 5, ISSN 0006-4971, pages 1044 - 1049, XP055041891 [Y] 1-22 * page 1044 - page 1045 *
 [Y]  - TUTT A ET AL, "TRISPECIFIC F(AB')3 DERIVATIVES THAT USE COOPERATIVE SIGNALING VIA THE TCR/CD3 COMPLEX AND CD2 TO ACTIVATE AND REDIRECT RESTING CYTOTOXIC T CELLS", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (19910701), vol. 147, no. 1, ISSN 0022-1767, pages 60 - 69, XP000863699 [Y] 1-22 * page 62 *
 [Y]  - W. SCHAEFER ET AL, "Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20110705), vol. 108, no. 27, doi:10.1073/pnas.1019002108, ISSN 0027-8424, pages 11187 - 11192, XP055003817 [Y] 1-22 * page 2 *

DOI:   http://dx.doi.org/10.1073/pnas.1019002108
 [A]  - J.J. Bosch et al, "MCSP/CD3-bispecific single-chain antibody construct engages CD4+ and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells", no. 5621, (20100421), AACR 101st Annual Meeting 2010, URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2521&sKey=ef81a5fa-b15c-4c4e-aa57-870b6479e274&cKey=a695d122-de20-451f-aeba-daf2b2a898f1&mKey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}, (20121023), XP002685799 [A] 1-22 * abstract *

DOI:   http://dx.doi.org/10.1158/1538-7445.AM10-5621
 [A]  - MILLER KATHY ET AL, "Design, construction, and in vitro analyses of multivalent antibodies", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20030501), vol. 170, no. 9, ISSN 0022-1767, pages 4854 - 4861, XP002508787 [A] 1-22 * the whole document *
by applicantUS4186567
 US4737456
 US4816567
 US5202238
 US5204244
 US5208020
 WO9411026
 US5416064
 EP0425235
 US5565332
 US5635483
 US5712374
 US5714586
 US5739116
 US5750373
 US5767285
 US5770429
 US5770701
 US5770710
 US5773001
 US5780588
 US5821337
 US5877296
 US5959177
 US5969108
 US6040498
 US6054297
 US6075181
 EP1017284
 US6150584
 US6171586
 US6267958
 US6417429
 US6420548
 US6630579
 US2004132066
 US2005079574
 US2005119455
 US2005260186
 US2005266000
 US6982321
 WO2006044908
 US7041870
 US2006104968
 US7087409
 US7125978
 US7189826
 US2007061900
 US2007117126
 US2007160598
 US2007237764
 US2007292936
 WO2008119567
 US2009002360
 US7498298
 US7521541
 US7527791
    - NAGORSEN; BÄUERLE, EXP CELL RES, (2011), vol. 317, pages 1255 - 1260
    - HOLLIGER ET AL., PROT ENG, (1996), vol. 9, pages 299 - 305
    - KIPRIYANOV ET AL., J MOL BIOL, (1999), vol. 293, pages 41 - 66
    - MOORE ET AL., BLOOD, (2011), vol. 117, pages 4542 - 51
    - SEIMETZ ET AL., CANCER TREAT REV, (2010), vol. 36, pages 458 - 467
    - KABAT ET AL., Sequences of Proteins of Immunological Interest, NIH PUBLICATION 91-3242, (1991), vol. 1-3
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - ALMAGRO; FRANSSON, FRONT. BIOSCI., (2008), vol. 13, pages 1619 - 1633
    - MORRISON, S.L. ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
    - HOUSTON, J.S., METHODS IN ENZYMOL., (1991), vol. 203, pages 46 - 96
    - KINDT ET AL., Kuby Immunology, W.H. FREEMAN AND CO., (2007), page 91
    - PORTOLANO ET AL., J. IMMUNOL., (1993), vol. 150, pages 880 - 887
    - CLARKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - LILJEBLAD ET AL., GLYCO J, (2000), vol. 17, pages 323 - 329
    - HEELEY, ENDOCR RES, (2002), vol. 28, pages 217 - 229
    - RODRIGUES ET AL., INT J CANCER, (1992), vol. 7, pages 45 - 50
    - NOOIJ ET AL., EUR J IMMUNOL, (1986), vol. 19, pages 981 - 984
    - FLATMAN ET AL., J. CHROMATOGR. B, (2007), vol. 848, pages 79 - 87
    - RODIGUES ET AL., INT J CANCER, (1992), vol. 7, pages 45 - 50
    - CHEN ET AL., J. MOL. BIOL., (1999), vol. 293, pages 865 - 881
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 10033
    - KASHMIRI ET AL., METHODS, (2005), vol. 36, pages 25 - 34
    - PADLAN, MOL. IMMUNOL., (1991), vol. 28, pages 489 - 498
    - DALL'ACQUA ET AL., METHODS, (2005), vol. 36, pages 43 - 60
    - OSBOURN ET AL., METHODS, (2005), vol. 36, pages 61 - 68
    - KLIMKA ET AL., BR. J. CANCER, (2000), vol. 83, pages 252 - 260
    - SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296
    - CARTER ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, page 4285
    - PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, page 2623
    - BACA ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 10678 - 10684
    - ROSOK ET AL., J. BIOL. CHEM., (1996), vol. 271, pages 22611 - 22618
    - VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL., (2001), vol. 5, pages 368 - 74
    - LONBERG, CURR. OPIN. IMMUNOL., (2008), vol. 20, pages 450 - 459
    - LONBERG, NAT. BIOTECH., (2005), vol. 23, pages 1117 - 1125
    - KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001
    - BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, page 86
    - LI ET AL., PROC. NATL. ACAD. SCI. USA, (2006), vol. 103, pages 3557 - 3562
    - NI, XIANDAI MIANYIXUE, (2006), vol. 26, no. 4, pages 265 - 268
    - VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, (2005), vol. 20, no. 3, pages 927 - 937
    - VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, (2005), vol. 27, no. 3, pages 185 - 91
    - HOOGENBOOM ET AL., Methods in Molecular Biology, HUMAN PRESS, (2001), vol. 178, pages 1 - 37
    - MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1992), vol. 222, pages 581 - 597
    - MARKS; BRADBURY, Methods in Molecular Biology, HUMAN PRESS, (2003), vol. 248, pages 161 - 175
    - SIDHU ET AL., J. MOL. BIOL., (2004), vol. 338, no. 2, pages 299 - 310
    - LEE ET AL., J. MOL. BIOL., (2004), vol. 340, no. 5, pages 1073 - 1093
    - FELLOUSE, PROC. NATL. ACAD. SCI. USA, (2004), vol. 101, no. 34, pages 12467 - 12472
    - LEE ET AL., J. IMMUNOL. METHODS, (2004), vol. 284, no. 1-2, pages 119 - 132
    - WINTER ET AL., ANN. REV. IMMUNOL., (1994), vol. 12, pages 433 - 455
    - GRIFFITHS ET AL., EMBO J, (1993), vol. 12, pages 725 - 734
    - HOOGENBOOM; WINTER, J. MOL. BIOL., (1992), vol. 227, pages 381 - 388
    - CHOWDHURY, METHODS MOL. BIOL., (2008), vol. 207, pages 179 - 196
    - CUNNINGHAM; WELLS, SCIENCE, (1989), vol. 244, pages 1081 - 1085
    - KAM ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 11600 - 11605
    - GERNGROSS, NAT BIOTECH, (2004), vol. 22, pages 1409 - 1414
    - LI ET AL., NAT BIOTECH, (2006), vol. 24, pages 210 - 215
    - GRAHAM ET AL., J GEN VIROL, (1977), vol. 36, page 59
    - MATHER, BIOL REPROD, (1980), vol. 23, pages 243 - 251
    - MATHER ET AL., Annals N.Y. Acad Sci, (1982), vol. 383, pages 44 - 68
    - URLAUB ET AL., PROC NATL ACAD SCI USA, (1980), vol. 77, page 4216
    - YAZAKI; WU, Methods in Molecular Biology, HUMANA PRESS, (2003), vol. 248, pages 255 - 268
    - ALMAGRO; FRANSSON, FRONT BIOSCI, (2008), vol. 13, pages 1619 - 1633
    - QUEEN ET AL., PROC NATL ACAD SCI USA, (1989), vol. 86, pages 10029 - 10033
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - MORRISON ET AL., PROC NATL ACAD SCI, (1984), vol. 81, pages 6851 - 6855
    - MORRISON; OI, ADV IMMUNOL, (1988), vol. 44, pages 65 - 92
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - PADLAN, MOLEC IMMUN, (1994), vol. 31, no. 3, pages 169 - 217
    - PADLAN, MOL IMMUNOL, (1991), vol. 28, pages 489 - 498
    - KLIMKA ET AL., BR J CANCER, (2000), vol. 83, pages 252 - 260
    - VAN DIJK; VAN DE WINKEL, CURR OPIN PHARMACOL, (2001), vol. 5, pages 368 - 74
    - LONBERG, CURR OPIN IMMUNOL, (2008), vol. 20, pages 450 - 459
    - Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - LONBERG, NAT BIOTECH, (2005), vol. 23, pages 1117 - 1125
    - "Epitope Mapping Protocols", MORRIS, Methods in Molecular Biology, HUMANA PRESS, (1996), vol. 66
    - HINMAN ET AL., CANCER RES., (1993), vol. 53, pages 3336 - 3342
    - LODE ET AL., CANCER RES., (1998), vol. 58, pages 2925 - 2928
    - KRATZ ET AL., CURRENT MED. CHEM., (2006), vol. 13, pages 477 - 523
    - JEFFREY ET AL., BIOORGANIC & MED. CHEM. LETTERS, (2006), vol. 16, pages 358 - 362
    - TORGOV ET AL., BIOCONJ. CHEM., (2005), vol. 16, pages 717 - 721
    - NAGY ET AL., PROC. NATL. ACAD. SCI. USA, (2000), vol. 97, pages 829 - 834
    - DUBOWCHIK ET AL., BIOORG. & MED. CHEM. LETTERS, (2002), vol. 12, pages 1529 - 1532
    - KING ET AL., J. MED. CHEM., (2002), vol. 45, pages 4336 - 4343
    - VITETTA ET AL., SCIENCE, (1987), vol. 238, page 1098
    - CHARI ET AL., CANCER RES., (1992), vol. 52, pages 127 - 131
 WO2010EP62527
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.